secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001708599-25-000029
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics posts FY 2024 net loss of $11.1M vs net income of $5.3M in 2023
--------------------------------------------------------------------------------

- Revenues fell to $56K from $3.2M; operating expenses rose to $17.1M from $6.3M.
- Cash and equivalents $3.7M at Dec 31, 2024; plus $5M from JuvVentures in Jan 2025, projected to fund through Q2 2025.
- R&D expense increased $5.1M to $7.5M, driven by SER-252 development and higher headcount.
- Sold UniverXome subsidiary in Dec 2024, eliminating $11.2M debt; $10M equity financing from JuvVentures secured.
- Appointed Karen J. Wilson and Dr. Jay Venkatesan to board; targeting first patient in Phase 1b trial for SER-252 in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000029/0001708599-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000029/ser-20250324.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer